Oyster Point Pharma Announces Retirement of William J. Link From Board of Directors
PRINCETON, N.J., March 17, 2022 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), a…
Year: 2022
CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022
SOUTH SAN FRANCISCO, Calif., March 17, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX),…
CinCor Pharma to be Added to Russell 2000® and Russell 3000® Indexes
BOSTON, March 17, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical…
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
TORONTO, March 17, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB:…
Century Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Updates
IND submission for lead program CNTY-101 on track for mid 2022; Phase 1 ELiPSE-1 trial…
NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation
GAITHERSBURG, Md., March 17, 2022 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI) and Zephyr AI (Zephyr)…
InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa
JENA, Germany, March 17, 2022 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical…
InMed Announces Management Changes
VANCOUVER, British Columbia, March 17, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the…
Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX:RVX) today announced the…
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
CLN-081 clinical data support a differentiated clinical profile; regulatory update planned for first quarter 2022…
Tilray Medical Expands Offering in Malta and Launches First Medical Cannabis Oil Products in Market
LEAMINGTON, Ontario, March 17, 2022 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”)…
Kane Biotech to Release Fourth Quarter and Full Year 2021 Financial Results on March 24 – Conference Call to Follow
WINNIPEG, Manitoba, March 17, 2022 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the…
ProMIS Neurosciences Announces Fiscal Year 2021 Results
TORONTO, Ontario and CAMBRIDGE, Massachusetts , March 17, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc….
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 24, 2022
NEW YORK and VIENNA, Austria, March 17, 2022 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ:…
MediWound Reports Fourth Quarter and Full Year 2021 Financial Results
Full-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46% Positive Top-Line Data for…
Evelo Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage…
Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
Over $140M in capital raised in initial public offering in 2021; Cash runway through first…
Alladapt Announces Initiation of Encore Open-Label Extension Study for its Harmony Phase 1/2 Study of ADP101 for Treatment of Food Allergy
Harmony remains ongoing, with OLE study intended to gain insights into long-term exposure to ADP101…
Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
-FYARRO™ approved November 22, 2021 and launched February 23, 2022- –FYARRO added to NCCN® Guidelines…
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
FDA review of NDA for FT218 is ongoing; commercial and launch preparations on-track to support potential commercial…